Tourette’s syndrome (TS) is a disease which has its onset during childhood and/or adolescence and is often life-long. Although the earliest descriptions of patients with motor and vocal tics were passed down from the ancient Greeks, Gilles de la Tourette was the first person who systematically described nine cases of the disorder that now bears his name, in 1885 when he was a student of Charcot at the Salpêtrière hospital in Paris. Gilles de la Tourette reported a positive family history in several of his nine original TS cases, raising the question of a genetic origin of the disorder. The etiology of TS, however, was subsequently ascribed to psychogenic causes until the 1950s. This perception began to change in the 1960s, when the beneficial effects of neuroleptic therapies such as repetitive transcranial magnetic stimulation and deep brain stimulation, are critically discussed.
drugs on the symptoms of TS began to be recognized. This observation helped to refocus attention from psychogenetic causes to Gilles de la Tourette’s view of biological central nervous system mechanisms.

In the following review, an overview of the advances made in the understanding of TS, with a special focus on the role of an infectious and inflammatory process, is provided.

**Clinical and epidemiological features of TS**

TS is clinically characterized by simple and/or complex motor tics and simple or complex vocal tics (Tables I and II), which cause marked distress or significant impairment in social or other important areas of functioning (Diagnostic and Statistical Manual of Mental Disorders. 4th ed [DSM-IV] criteria). Sensory tics such as body sensations, eg, cold, heat, heaviness, urging, and touching, which often precede a motor tic, have been described in a large number of TS patients. In sensory tics, the motor action acts as a response to an internal or external stimulus.

A characteristic of TS is its great variability of symptoms. Motor, vocal, and sensory tics start during childhood/adolescence, and show a waxing and waning course, with exacerbations in periods of emotional stress; however, periods without such obvious symptoms are also typical. Symptoms other than tics such as echolalia and echopraxia, palilalia, coprolalia, mutilations, and disturbed impulse control characteristically often occur, although they are not obligatory for the diagnosis of TS. Furthermore, obsessions and compulsions, cognitive dysfunction, or affective disturbances such as depression or anxiety have frequently been described in these patients. An increased comorbidity of TS and obsessive-compulsive disorder (OCD), mood disorders, and anxiety, as well as phobias and attention deficit/hyperactivity disorder (ADHD) have been reported. Increased substance abuse has been suggested, since the sedative effect of alcohol often improves the tics. However, systematic studies of substance abuse or dependency in TS are lacking.

Since the onset of TS is before the age of 18 (DSM-IV) and often leads to severe psychosocial impairment, children and adolescents suffering from TS are often discriminated against and have disadvantages in terms of psychosocial development. Moreover, the 50% to 60% comorbidity with ADHD or OCD additionally contributes to the impaired development of personality during the critical period. Furthermore, these patients are also more likely to experience academic as well as psychosocial problems, and these conditions may contribute to a chronification of the disorder on the one hand and to the development of personality disorders on the other.

The prevalence of TS is estimated at about 4 to 5 per 10 000 according to the internationally accepted American estimation of prevalence (DSM-IV). Studies relying on stricter methodological criteria describe a prevalence between 0.7 and 5.3 per 10 000. Other findings suggest that, especially in males, the prevalence is up to 1% of the population. The male:female ratio for TS is around 4:1.

**Delayed diagnosis of TS**

The estimated time from onset of the first symptoms of TS to the time the final diagnosis is established is about 5 to 10 years. Since TS is characterized by severe socially...
disabilitating symptoms, this delay causes additional negative reactions, and leads to significant psychosocial suffering in many cases. Although controlled data are still lacking, there are indications that the course of TS and the patient’s capacity to cope with it will be more favorable in cases where TS is diagnosed earlier. The high comorbidity with emotional instability and personality disorders may result at least partly from these problems.

**TS: a syndrome of different etiologies and variable phenomenology**

Clinically, the symptoms of TS show a broad variability; however, whether this variability corresponds to differences in the outcome as well as to the response to special treatments has not been investigated. Furthermore, different etiological factors may contribute to TS. There is no doubt that genetic factors which have not yet been specified do play a pivotal role. Neurochemical and pharmacological studies suggest a functional hypersensitivity of dopaminergic neurotransmission and a dysfunction of the opiateergic system. Probably, the disturbance of the dopaminergic neurotransmission is the final stage of different pathogenetic pathways. Neurophysiological studies have shown reduced neuronal inhibition within the sensorimotor loop, with good frontocortical compensatory mechanisms. Within a subgroup of TS patients, recurrent or chronic inflammation may lead to a manifestation of tics. Recently, the diagnosis of postinflammatory immune processes after streptococcal infections associated with tics or obsessive-compulsive (OC) symptoms, known as pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) has been established in the USA. Furthermore, TS symptomatology can be the result of trauma, of intoxication, or of pharmacological treatment. There is evidence that long-term treatment with classic neuroleptics, as well as treatment of ADHD with stimulants, might increase the risk of tic development in some children.

**Differential diagnosis of TS**

Due to the high variability of TS symptoms, the diagnosis of TS is often difficult. Since the typical course is one of exacerbations and remissions, typical vocal or motor tics often do not occur during the symptom-free intervals, although these patients still suffer from other—often comorbid—symptoms, hampering the TS diagnosis. Mutilations, obsessive-compulsive (OC) symptoms, or other behavioral “abnormalities” often dominate the clinical symptoms. Moreover, patients suffering from TS often describe their motor and vocal tics as compulsions. Moreover, the suppression of tics for a certain time is a diagnostic feature of TS, especially in situations where the patient’s attention is drawn to them (eg, during a medical examination). In particular, typical but awkward symptoms such as coprolalia, copropraxia, or echolalia, are often concealed.

Regarding the differential diagnosis of TS (*Table III*), other tic disorders such as chronic motor tic disorder, which lacks vocal tics, must be excluded. In cases where the disorder starts later than the consensus age of 18 or 21 years, even full-blown TS symptoms cannot be diagnosed as TS (*DSM-IV*). Extrapyramidal movement disorders, but also OC symptoms, are known to occur as a symptom of poststreptococcal disease, such as in Sydenham’s chorea, for a long time. Huntington’s disease, today easily diagnosed by molecular genetic methods, is a movement disorder often showing similar phenomena to TS; this differential diagnosis needs to be kept in mind. Pharmacologically induced hyperkinesia, induced by, eg, L-dopa or amphetamine, is an important differential diagnosis, but tardive dyskinesias, caused by antipsychotic therapy, often show similar motor symptoms to tics. Moreover, schizophrenia is often associated with movement abnormalities such as stereotypic movements and motor automatisms, the latter also frequently found in organic brain disorders. This has to be considered as well, particularly since schizophrenia and TS have common pathogenetic features and co-occur in certain cases. Apart from schizophrenia, psychogenic movement disorders are an important psychiatric differential diagnosis in TS.

Neuroacanthocytosis is another group of neuropsychiatric disorders which shows features of TS. Primarily, it is characterized by abnormal erythrocytes in the blood.

**Table III. Differential diagnosis of Tourette syndrome.**

| Pharmacologically induced hyperkinesias (L-dopa, amphetamine) |
| Huntington’s disease |
| Sydenham’s chorea |
| Metabolic disturbances (eg, Wilson’s disease) |
| Schizophrenic stereotypes |
| Tardive dyskinesias |
| Motor automatisms |
| Psychogenic movement disorders |

*Note: The table above lists the characteristics of Tourette syndrome.*
Acanthocythes, which seem to be the result of a hereditary component and represent an impairment of structural proteins of the cellular membrane. The first symptom of neuroacanthocytosis is often an epileptic seizure, but OC symptoms, symptoms of ADHD, or tics are described as manifestations of the condition. In some recent studies, patients primarily presenting with tics, genetic defects belonging to the group of neuroacanthocytosis syndromes, such as chorea-acanthocytosis, have been reported.

**TS is not only a movement disorder, but a psychiatric disorder**

Because of its rich clinical expression and frequent association with comorbid disorders, the spectrum of TS is often not recognized or fully appreciated. As our knowledge about TS expands, however, it is becoming increasingly obvious that TS is not merely a movement disorder, manifested by motor and vocal tics, but a relatively common neurobehavioral complex manifested, in addition to tics, by attention deficit, OC symptoms, lack of impulse control, and a variety of other behavioral symptoms. Since most cases of TS are mild and do not provoke medical diagnosis and treatment, the patients seen in the clinic represent only the tip of the iceberg. Although no valid data exist regarding the frequency of substance abuse, there is no doubt that many persons suffering from TS show a comorbid substance abuse. Alcohol and sedative drugs such as benzodiazepines have a short-term effect on tics and other symptoms of TS, leading to a high prevalence of alcohol abuse, which is estimated at about 30% in our own sample (Muller, unpublished observation). Due to the early onset of tics, many children affected with tics are socially withdrawn; they become outsiders in their families and peer groups. This might promote the development of personality disorders, which have been described in 60% of TS patients. A comorbid depressive syndrome is found in about a quarter of affected persons. Markedly higher is the rate of comorbidity with ADHD, observed in 55% of the TS patients. The comorbidity with OCD appears to be even higher, having been described in 40% to 90% of the patients. However, due to the broad overlap of tics, in particular complex tics and OC symptoms, there is some discussion as to whether “specific” compulsions such as symmetry behavior, echophenomena, or touching should be classified as tics or as OC behavior.

**Neurobiological characteristics of TS**

Although TS is a disorder of primarily the dopaminergic system of the basal ganglia, there is no doubt that cortical structures are also involved. The hypothesis of Kurlan, in particular, focuses on disinhibition within the cortical-striatal-thalamic motor loop, including the limbic system. Similar conclusions were drawn by studies using transcranial magnetic stimulation, which show reduced intracortical inhibition in TS patients. We found that disturbed saccadic eye movements are in keeping with the hypothesis of a disturbed activation of the frontal cortex by ascending loops from the basal ganglia. Moreover, the disturbed inhibition of unwanted orientation reactions revealed by antisaccades, as well as the known attention problems, favor a functional impairment of the frontal cortex in TS.

**Brain morphology of TS**

A neuroimaging study in adult TS patients without long-term antipsychotic treatment revealed smaller mean volumes of the caudate, lenticular, and globus pallidus nuclei compared with controls, on both the right and left. Further analyses of basal ganglia asymmetry indices suggest that TS basal ganglia do not have the volumetric asymmetry (left greater than right) seen in normal controls. Similar findings were reported by other researchers studying a group of TS children: statistical comparisons between TS patients, with (n=18) or without (n=19) ADHD, and controls showed significant differences in the volume of the left globus pallidus and in lenticular asymmetry. Interestingly, caudate volumes in children with TS predict the severity of tic and OC symptoms in early adulthood. This study provides compelling evidence that morphologic disturbances of the caudate nucleus within cortico-striatal-thalamo-cortical circuits are central to the persistence of both tics and OC symptoms into adulthood. These findings strongly support the view that TS is related to a basal ganglia dysfunction, although several other brain regions are involved in the pathophysiology of tics as hypothesized by the concept of Kurlan and shown by functional magnetic resonance imaging (MRI). Interestingly, neuroimaging data in TS also show significantly increased white matter lesions in the basal ganglia and other brain regions, a finding that will be discussed in the context of the inflammatory hypothesis of TS.
Genetics of TS

There is evidence for a strong genetic background of TS. It has been demonstrated in twin studies that monozygotic twins are more often concordant for the presence of TS in up to 53% or any tics in up to 77% compared with dizygotic twins (up to 8% concordant for TS and 23% for any tics). While it is evident that genetic factors play a profound role, the phenotype may be variable and may not be confined to full-blown TS.

The risk for TS is sex-dependent: 11.5% for brothers of an affected person and 4.8% for sisters. The frequency of TS in first-degree relatives ranges from 9.8% to 15%, according to the study cited. A particular risk gene for TS, however, has not yet been identified. Although large linkage studies have been performed, a genome-wide screen for linkage using 386 markers did not show a limit of detection (LOD) score of more than two, nor did a genome-wide screen based on 110 sib pairs, show significant loci. A sample from a French-Canadian family (127 members, 20 to 40 affected) showed a LOD score greater than three on 11q23. However, the incomplete genetic penetrance, the high variability of the phenotype (symptoms), possible different etiological factors, and several other concomitant factors complicate genetic studies in TS.

TS as an inflammatory disease

Recent studies suggest that an inflammatory process, due to an acute or chronic infection or a postinfectious immune response, may be involved in the pathogenesis of TS. Although the pathological mechanism in TS is unclear, contribution of an immunological dysfunction or an inflammatory process has been discussed. With regard to research on immune function in TS, most studies have focused on antibody production. Increased antibody production including antiphospholipid and antineural antibodies directed against structures in the basal ganglia has been described. Recent research, however, showed conflicting results regarding increased antineural antibodies in the serum of TS. D8/17, a surface marker on antibodies producing B-lymphocytes, has been described to be a diagnostic marker in OCD and in tics, but this has not been confirmed. However, increased titers of antiphospholipid antibodies, and increased IgE levels have been described in TS. In recent years, immunological research in TS has focused on cytokines. In a recent prospective longitudinal study, increased serum levels of the cytokines interleukin (IL)-12 and tumor necrosis factor (TNF)-α in juvenile TS patients were observed. During exacerbations of tics, a further increase in IL-12 and TNF-α was observed, pointing to a relationship between tic severity and proinflammatory cytokines. In OCD, however, decreased levels of TNF-α were described. Since OCD and TS show a high rate of comorbidity, a possibly discriminative marker—decreased in OCD and increased in TS—would be very valuable. Although the results of the kynurenine estimations in TS are divergent, depending on interfering factors, changes in the kynurenine levels in the sera of TS patients also point to the involvement of the immune system. Kynurenine is the product of activated monocytes/macrophages; changes in kynurenine production take place during inflammatory processes. Moreover, kynurenine and other products of the tryptophan/kynurenine-metabolism are neuroactive proteins, possibly themselves contributing to changes in neurotransmitter metabolism. Moreover, increased levels of the soluble adhesion molecules V-CAM-1 and E-selectin—increased in inflammatory states—were reported in children and adults suffering from TS. A case report of successful treatment with a cyclo-oxygenase (COX)-2 inhibitor also promotes the view that an inflammatory process is involved in TS.

Inflammation in TS as a result of an infectious or postinfectious process

It has been described that tics appear or are exacerbated in acute Lyme disease, or infection with Mycoplasma pneumoniae, or acute streptococcal infection. Moreover, an association of the common cold with tic disorders has been observed. Improvement or remission of the tics has been associated with antibiotic therapy. These findings strongly suggest that infectious agents contribute to the pathogenesis of tics and TS. PANDAS has been extensively described during recent years. The main symptoms of PANDAS are motor and vocal tics and OC behavior like that found in TS. Although crossreacting antibodies against the putamen have been observed in PANDAS, the mechanism has not yet been established. TS is proposed to be a part of PANDAS. Increased antibody titers and other features of PANDAS, however, have also been described in adult TS patients, while the PANDAS concept is restricted...
to children. Antibodies against certain streptococcal M proteins, ie, proteins on the surface of streptococci which are known to be responsible for the virulence and the immune properties of the particular streptococcal strain, are increased in children and adult TS patients. In particular, antibodies against M12 and M19, which are known to crossreact with brain cells, are increased in these patients, while no difference could be detected in other, more frequent M-protein antibody titers.76 This finding—in addition to others with cross-reacting antibodies—shows that a poststreptococcal autoimmune process is involved in TS. This is the basis for the successful application of immune-modulating therapeutic approaches in TS and PANDAS.72

Different types of infectious agents and different stages of infection—eg, acute streptococcal infection77 and poststreptococcal inflammation,75 were reported to be associated with TS. The therapy, however, has to take into consideration different therapeutic strategies for acute or chronic infection, or for a postinfectious autoimmune process. Therefore—although there are continuous transitions between these inflammatory states—research should focus on the differentiation and differential therapies of these stages of inflammation.

Anti-inflammatory therapy in TS, eg, use of a COX-2 inhibitor, has also shown positive effects.65 Altogether, the involvement of inflammatory immunological mechanisms in the pathogenesis of TS, at least in a subgroup of patients, is obvious. A multifactorial pathogenesis has been proposed, with the involvement of an (immuno)genetic predisposition and environmental factors such as infection or postinfectious phenomena. Further research also has to identify markers for the differentiation of inflammation-mediated and other forms of TS.

Recent findings from T2-weighted MRI in patients with TS, but also other syndromes (OCD and ADHD, which show a high prevalence of comorbidity with TS) revealed a significantly higher frequency of cortical and subcortical hyperintensities compared with controls, a finding which is in accordance with an inflammatory process in certain cases of TS.37

**Shortcomings of the PANDAS concept**

The PANDAS concept, however, is limited by several shortcomings. Although this disorder is associated with streptococcal infection, no test for streptococci to support the infection, is required for the diagnosis. An objective parameter supporting the clinical diagnosis (eg, increased antistreptococcal titers) would help to confirm the diagnosis.

Moreover, different stages of streptococcal infection might lead to different therapeutic consequences. Although acute and chronic infection with streptococci require antibiotic treatment, a poststreptococcal autoimmune process may respond better to immunomodulatory therapy. A further difficulty for the PANDAS diagnosis might be the heterogeneity of the symptoms, which include not only motor and vocal tics, but also OC symptoms, which often, but not necessarily, co-occur in one child. The restriction of the PANDAS concept to children/adolescents, however, is a further point for discussion. Tics and OC symptoms also often occur in adults. Accordingly, an association between tics and infectious agents in adults has been reported.67,78 Although it is known that children and adolescents are more vulnerable to certain infections, the association between tics, OC symptoms, and infection is not restricted to this population. Moreover, studies have shown that not only streptococci but also other infectious agents such as *Borrelia Burgdorferi* or *Mycoplasma Pneumoniae* are associated with tics, ie, the association of tics and infectious agents is not restricted to streptococci. A broader concept of this association, however, would more fulfill the needs for an infectious concept of TS.

**Conventional pharmacotherapeutic concepts of TS**

There is no doubt that dopaminergic neurotransmission is involved in the pathophysiology of TS. Dopamine (D2) receptor blocking agents such as haloperidol or pimozide have been shown to be effective in TS in several studies.79 Haloperidol showed an efficacy between 78% and 91% in 41 reports over a 14-year period. Many patients, however, discontinue haloperidol due to extrapyramidal side effects, while pimozide showed a superior profile regarding side effects. Pimozide was effective in several double-blind, placebo-controlled studies.80 There are also reports of effective treatment with drugs such as fluphenazine, penfluridol, trifluoperazine, and flupenthixol.81 In the meantime, atypical antipsychotics such as risperidone, which is not only a D2 receptor antagonist, but also a serotonin (5-HT)3 antagonist, has been shown to be effective in TS.82,83 Clozapine was observed to be effective against tics,84 although there have also been negative
results reported. A partial control of tics during therapy with olanzapine at a dose of 5 to 10 mg/day was reported, as well as a reduction in tics in a controlled study (n=4). Ziprasidone, at a dose of 5 to 40 mg/day, was shown to be significantly more effective than placebo in 28 patients (7 to 17 years old) in a double-blind, randomized study, and was well tolerated. It should be noted, however, that the sudden death of a TS patient under therapy with ziprasidone during a clinical trial was reported. Aripiprazole, a new atypical antipsychotic that acts as a dopaminergic modulator showing mixed dopamine antagonistic and agonistic effects, may take a special position in the therapy of TS. Effective treatment of TS using aripiprazole was reported repeatedly, in contrast to those treated with other antipsychotics, a number of patients showed complete recovery from tics without significant adverse effects. The drug of first choice, for therapy of tics, particularly for children in many European countries, is tiapride, a benzamide deriviate, which selectively blocks dopamine in the basal ganglia. Although only double-blind, placebo-controlled studies show beneficial effects on movement disorders and tics, tiapride is widely used in countries such as Germany, France, and others. It is one of the few drugs which is prescribed not only in adults, but also in children. In contrast to several antipsychotics, however, no adverse effects on cognitive performance in children have been observed. However, clonidine, a central α₂-adrenoceptor agonist reducing noradrenergic activity in the central nervous system, has also been reported to be effective in TS, although controversial effects of clonidine in different studies were shown in a dose of 3 to 5 µg/kg body weight. Possibly, the beneficial effects of clonidine on behavioral abnormalities are more pronounced than on vocal and motor tics. In general, antipsychotics seem to be more effective compared with clonidine. The effect of clonidine, however, shows that noradrenergic neurotransmission is also involved in TS. Furthermore, the differentiation and characterization of subgroups may lead to different therapeutic strategies, for example, early antibiotic treatment in cases in which tics are the result of infection may help to prevent progression to chronic stages which otherwise have to be treated with neuroleptics. Therapy with immunoglobulin IV and plasmapheresis as immunomodulatory treatment strategies are currently the objective of therapeutic trials. Treatment with cannabinoids, in particular 19-tetrahydrocannabinol, has shown beneficial effects in single cases, but a randomized, double-blind study failed to show convincing effects.

Behavior therapy

Until the introduction of haloperidol, TS was thought to be a psychogenic syndrome; psychoanalytic therapeutic concepts were very common and widely practiced. This concept totally changed during recent decades. However, supportive psychotherapy and training in coping strategies, supported by concepts of self-help care, are known to be very important, in particular in such a chronic and socially isolating disease. Although tics and other symptoms can not be influenced decisively, behavior-therapy techniques, including progressive muscle relaxation as well as learning and training of alternative behavior, can reduce the tic intensity and frequency. This technique of habit reversal is based on the identification of tic-preceding sensations (premonitory urges).

Experimental therapeutic approaches in TS

Immunomodulatory and anti-inflammatory therapies

For children with PANDAS, effective treatment with immunomodulatory substances or techniques have been described repeatedly. These therapies include IV immunoglobulin G (IgG) and plasmapheresis, the latter showing even better results than IV IgG. Keeping in mind the critical view of PANDAS, these immunomodulatory therapies might also reveal favorable effects in TS patients not fulfilling PANDAS criteria. Effective IV IgG therapy has been described in TS. In the case of an acute or possibly also a chronic infection associated with tics, the TS symptoms including motor and vocal tics are cured by antibiotics. This has been reported for infection with *Lyme-Borreliosis*, *Mycoplasma Pneumoniae*, and streptococci. In a retrospective, open-label study in 34 TS patients, the effects and predicting variables for therapeutic effects of IV IgG versus antibiotics were evaluated. It was observed that increased antistreptococcal titer of antiDNase predicted better effects of antibiotics, and increased anti-chlamydial titers better effects of IV IgG. Around 60% of the total sample showed a therapeutic response to either immunomodulatory treatment. These interesting, but very preliminary, results require further controlled studies.
Moreover, anti-inflammatory treatment with the COX-2 inhibitor celecoxib was described to be effective in TS in a single case, a result also requiring further examination.

**Repetitive transcranial magnetic stimulation**

A small, open-label study using repetitive transcranial magnetic stimulation (rTMS) over the supplementary motor area of 10 TS patients showed clinically significant improvement of TS and accompanying OCD symptoms, with benefits lasting up to 3 months in almost two thirds of the patients. Other studies, however, failed to bring about improvement using another application of rTMS, while in a crossover trial using high-frequency stimulation of the left prefrontal cortex, a significant improvement of the tics was observed. At this stage of knowledge, further studies have to be performed in order to optimize the localization, the technique, and the number of rTMS-applications, and the sustainability of the effects. RTMS seems a promising method, although it requires elaborate and costly equipment, because it shows only marginal side effects.

**Electroconvulsive therapy**

Single case reports describe therapeutic effects of electroconvulsive therapy (ECT) on motor tics, vocal tics, and OC behavior. Maintenance ECT therapy (one treatment every 4 to 6 weeks) was reported to be effective in a therapy-resistant case of TS. Those reports reveal that ECT is a therapeutic option in treatment-resistant cases of TS.

**Deep brain stimulation**

During recent years, surgical deep brain stimulation, known to be effective in Parkinson’s disease and certain dystonic syndromes, has been increasingly performed in treatment-resistant cases of TS. Stimulation electrodes were placed in various locations. Bilateral stimulation of the thalamus showed moderate improvement of the tics in five cases. Bilateral stimulation of the globus pallidus internus showed good and very good results in two cases, while bilateral stimulation of the nucleus accumbens revealed moderate improvement of tics and OC symptoms.

**Conclusion**

Although important progress in our knowledge about TS has been made during the last few decades, this syndrome is still poorly understood. The pathophysiology is unknown, but therapeutic strategies are more and more successful. During recent years, the role of inflammation, due to infection associated with a dysfunction of the immune system, has come more into the focus of interest. In addition to a broad spectrum of promising new experimental therapeutic approaches, future research will put emphasis on the role of inflammation, on the differentiation and differential therapies of these stages of inflammation, and on the identification of markers for the differentiation of inflammation-mediated and other forms of TS, because TS is a syndrome of different etiologies and variable phenomenology.

**REFERENCES**

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome. Am J Psychiatry. 1993;150:98-102.
3. Müller N, Putz A, Kathmann N, Lehle R, Günther W, Straube A. Differentiation of obsessive-compulsive symptoms in Tourette's syndrome, Parkinson's disease and obsessive-compulsive disorder. Psychiatry Res. 1997;70:105-114.
4. Shapiro AK. Gilles de la Tourette Syndrome. New York, NY: Raven Press: 1988.
5. Leckman JF, Cohen DJ. Tourette's Syndrome - Tics, Obsessions, Compulsions: Developmental Psychopathology and Clinical Care. New York, NY: Wiley; 1999.
6. Leonard HL, Lenane MC, Svedo SE, Rettew DC, Gershon ES, Rapoport JL. Tics and Tourette’s disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children. Am J Psychiatry. 1992;149:1244-1251.
7. Pauls DL, Cohen DJ, Heimbuch R, Detlor J, Kidd KK. Familial pattern and transmission of Gilles de la Tourette syndrome and multiple tics. Arch Gen Psychiatry. 1981;38:1091-1093.
8. Pauls DL, Leckman JF, Cohen DJ. Evidence against a genetic relationship between Tourette's syndrome and anxiety, depression, panic and phobic disorders. Br J Psychiatry. 1994;164:215-221.
9. Pitman RK, Green RC, Jenike MA, Mesulam MM. Clinical comparison of Tourette’s disorder and obsessive-compulsive disorder. Am J Psychiatry. 1987;144:1166-1171.
10. Comings DE, Comings BG. A controlled study of Tourette syndrome. III. Phobias and panic attacks. Am J Hum Genet. 1987;41:761-781.
11. Comings BG, Comings DE. A controlled study of Tourette syndrome. V. Depression and mania. Am J Hum Genet. 1987;41:804-821.
12. Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry. 1996;53:437-446.
13. Pauls DL, Leckman JF, Cohen DJ. Familial relationship between Gilles de la Tourette's syndrome, attention deficit disorder, learning disabilities, speech disorders, and stuttering. J Am Acad Child Adolesc Psychiatry. 1993;32:1044-1050.
**Síndrome de la Tourette: características clínicas, fisiopatología y aproximaciones terapéuticas**

*El síndrome de la Tourette (ST) es un trastorno caracterizado por tics motores simples y complejos, tics vocales y frecuentemente síntomas obsesivo-compulsivos. Se presenta antes de los 21 años. Tipicamente el ST muestra un curso con fluctuaciones, pero con frecuencia se observa una cronificación de los tics, aun durante las últimas etapas de la vida. El ST se presenta de preferencia en niños varones y muestra una herencia genética con penetrancia variable. El mecanismo patológico aun no está aclarado. Los estudios neuroanatómicos y de neuroimágenes, al igual que el tratamiento efectivo con neurolépticos sugiere que una alteración del sistema dopaminérgico en los ganglios basales tiene un papel importante en su patogénesis. Se discuten algunos posibles mecanismos causales del trastorno de la neurotransmisión dopaminérgica, con un principal énfasis en el proceso inflamatorio inmune activado por la infección. Se sabe que los trastornos de los movimientos extrapiramidales ocurren como síntoma de enfermedades estreptocócicas, como en el corea de Sydenham. Se ha propuesto que algunos casos de ST en la niñez sean causados por tal mecanismo postestreptocócico, siendo parte del espectro de trastornos neuroconductuales de la niñez llamado PANDAS (trastorno neuropsiquiátrico pediátrico autoinmune asociado con enfermedad estreptocócica). Se discute la sobreposición entre ST y PANDAS y se presenta una visión crítica del concepto de PANDAS. Se describen las repercusiones terapéuticas de los diferentes mecanismos patológicos, tomando en consideración no sólo la naturaleza aguda o crónica de las diferentes infecciones, sino también un proceso autoinmune. Además se discuten críticamente las estrategias terapéuticas que utilizan antipsicóticos típicos y atípicos como también terapias experimentales como la estimulación magnética transcraneal repetitiva y la estimulación cerebral profunda.*

**Syndrome de Gilles de la Tourette : tableau clinique, physiopathologie et approches thérapeutiques**

*Le syndrome de Gilles de la Tourette (SGT) est une maladie caractérisée par des tics moteurs simples et complexes et par des symptômes obsessionnels-compulsifs fréquents. Il débute avant l’âge de 21 ans. Le SGT suit habituellement une évolution croissante puis décroissante, mais une chronicisation des tics, même à l’âge adulte, est fréquente. Le SGT se rencontre principalement chez les garçons, avec une héritabilité génétique à pénétrance variable. Le mécanisme pathologique reste encore obscur. Les études de neuroanatomie et de neuro-imagerie, ainsi que l’efficacité des traitements utilisant des antipsychotiques, suggèrent qu’un trouble du système dopaminergique dans les ganglions basales est une des causes de cette maladie. Certaines études suggèrent également que les tics moteurs peuvent être causés par une infection streptococcique, comme dans la chorée de Sydenham. Certains cas de SGT juvéniles seraient peut-être pro-voqués par un tel mécanisme post-streptococcique, appartennant à l’éventail des troubles neurocomportementaux de l’enfance appelé trouble neuro-psychiatrique auto-immun pédiatrique associé à une infection streptococcique (PANDAS). Le chevauchement entre le SGT et le PANDAS est débattu et le concept de PANDAS est présenté dans l’article. Les implications thérapeutiques des différents mécanismes pathologiques sont décrites en prenant en compte non seulement la nature aiguë ou chronique des différentes infections, mais aussi l’existence d’un processus auto-immun. Les stratégies thérapeutiques utilisant des antipsychotiques typiques et atypiques ainsi que les traitements expérimentaux tels que la stimulation magnétique transcrânienne répétitive et la stimulation cérébrale profonde, sont de plus revus de manière critique.*
Clinical research

14. Hirschmüller A, Bartels M. [A case of Gilles de la Tourette syndrome with strong mutation tendencies]. Nervenarzt. 1982;53:670-673.

15. Tanner CM, Goldman SM. Epidemiology of Tourette syndrome. Neurol Clin. 1997;15:395-402.

16. Apter A, Pauls DL, Bleich A, et al. An epidemiologic study of Gilles de la Tourette’s syndrome in Israel. Arch Gen Psychiatry. 1993;50:734-738.

17. Robertson MM, Stern JS. Gilles de la Tourette syndrome. Br J Hosp Med. 1997;58:253-256.

18. Freeman MP. Omega-3 fatty acids in psychiatry: a review. Ann Clin Psychiatry. 2000;12:159-165.

19. Rothenberger A. Electrical brain activity and motor control in Tourette’s Syndrome and attention deficit hyperactivity disorder. Neuroimaging in Childhood Neurodevelopmental Disorders. Berlin, Heidelberg: Springer; 1998:141-151.

20. Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Migracy and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med. 2003;9:914-920.

21. Asbahr FR, Garey MA, Snider LA, Janetta DM, Elkins H, Swedo SE. Obsessive-compulsive symptoms among patients with Sydenham chorea. Biol Psychiatry. 2005;57:1073-1076.

22. Müller N, Riedel M, Zawta P, Günther W, Straube A. Comorbidity of Tourette’s syndrome and schizophrenia—biological and physiological parallels. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1245-1252.

23. Danek A, Walker RH. Neuroacanthocytosis. Curr Opin Neurol. 2005;18:386-392.

24. Bohlega S, Al-Jishi A, Dobson-Scott C, et al. Chorea-acanthocytosis: clinical and genetic findings in three families from the Arabian peninsula. Mov Disord. 2003;18:403-407.

25. Saiki S, Sakai K, Kitagawa Y, Saiki M, Kataoka S, Hirose G. Mutation in the CHAC gene in a family of autosomal dominant chorea-acanthocytosis. Neurology. 2003;61:1614-1616.

26. Saiki S, Hirose G, Sakai K, et al. Chorea-acanthocytosis associated with Tourettism. Mov Disord. 2004;19:833-836.

27. Robertson MM, Banerjee S, Hiley PJ, Tannock C. Personality disorder and psychopathology in Tourette’s syndrome: a controlled study. Br J Psychiatry. 1997;171:283-286.

28. Burd L, Freeman RD, Klug MG, Kerbeshian J. Tourette Syndrome and learning disabilities. BMC Pediatr. 2005;5:34.

29. Nee LE, Caine ED, Polinsky RJ, Eldridge R, Ebert MH. Gilles de la Tourette syndrome: clinical and family study of 50 cases. Ann Neurol. 1980;7:41-49.

30. Kurlan R. The pathogenesis of Tourette’s syndrome. A possible role for hormonal and excitatory neurotransmitter influences in brain development. Arch Neurol. 1992;49:874-876.

31. Ziemann U, Paulus W, Rothenberger A. Decreased motor inhibition in Tourette’s disorder: evidence from transcranial magnetic stimulation. Am J Psychiatry. 1997;154:1277-1284.

32. Straube A, Mennicken JB, Riedel M, Eggett T, Müller N. Saccades in Tourette’s disorder: evidence from transcranial magnetic stimulation. Arch Neurol. 1998;55:495-498.

33. Musil M, Kühler R, Ziemann U, Rothenberger A. Decreased motor inhibition in Tourette’s syndrome. J Psychiatr Res. 1999;33:509-536.

34. Eapen V, Pauls DL, Robertson MM. Evidence for autosomal dominant transmission in Tourette’s syndrome. United Kingdom cohort study. Br J Psychiatry. 1993;162:593-6:593-596.

35. Hebebrand J, Klug B, Fimmers R, et al. Rates for tic disorders and obsessive compulsive symptomatology in families of children and adolescents with Gilles de la Tourette syndrome. J Psychiatr Res. 1997;31:519-530.

36. Barr CL, Wigg KG, Pakstas AJ, et al. Genome scan for linkage to Gilles de la Tourette syndrome. Am J Med Genet. 1999;88:437-445.

37. The Tourette Syndrome Association International Consortium for Genetics. A complete genome screen in sib pairs affected by Gilles de la Tourette syndrome. Am J Hum Genet. 2000;67:1008-1013.

38. Merette C, Brasard A, Potvin A, et al. Significant linkage for Tourette syndrome in a large French Canadian family. Am J Hum Genet. 2005;57:1073-1076.

39. Kissing LS, Marcotte AC, Culpepper L. Antineuronal antibodies in movement disorders. Pediatrics. 1993;92:39-43.

40. Singer HS, Giuliano JD, Hansen BH, et al. Antibodies against human putamen in children with Tourette syndrome. Neurology. 1998;50:1618-1624.

41. Wendlandt JT, Grus FH, Hansen BH, Singer HS. Striatal antibodies in children with Tourette’s syndrome: multivariate discriminant analysis of IgG repertoires. J Neuroimmunol. 2001;119:106-113.

42. Martino D, Giovannoni G. Autoaggressive immune-mediated mediated movement disorders. Adv Neurol. 2005;96:320-335.

43. Church AJ, Dale RC, Giovannoni G. Anti-basal ganglia antibodies: a possible diagnostic utility in idiopathic movement disorders? Arch Dis Child. 2004;89:611-614.

44. Singer HS, Hong JY, Yoon DY, Williams PN. Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. Neurology. 2005;65:1701-1707.

45. Dale RC, Church AJ, Candler PM, Chapman M, Martino D, Giovannoni G. Serum autoantibodies do not differentiate PANDAS and Tourette syndrome from controls. Neurology. 2006;66:1612.

46. Loiselle OR, Wendlandt JT, Rohde CA, Singer HS. Antistreptococcal, neuronal, and nuclear antibodies in Tourette syndrome. Pediatr Neurol. 2005;33:119-125.

47. Murphy TK, Goodman WK, Fudge MW, et al. B lymphocyte antigen D8/17: a peripheral marker for childhood-onset obsessive-compulsive disorder and Tourette’s syndrome? Am J Psychiatry. 1997;154:402-407.

48. Morer A, Vinas O, Lazaro L, Bosch J, Toro J, Castro J. DB/17 monoclonal antibody: an unclear neuropsychiatric marker. Behav Neurol. 2005;15:161-8.

49. Finegold I. Allergy and Tourette’s syndrome. Ann Allergy. 1985;55:119-121.

50. Hoekstra PJ, Bijzet J, Limburg PC, et al. Elevated D8/17 expression on B lymphocytes, a marker of rheumatic fever, measured with flow cytometry in tic disorder patients. Am J Psychiatry. 2001;158:605-610.

51. Leckman JF, Katzovitch L, Kavikova I, et al. Increased serum levels of interleukin-12 and tumor necrosis factor-alpha in Tourette’s syndrome. Biol Psychiatry. 2005;57:667-673.

52. Brambilla F, Pernia G, Bellodi L, et al. Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol Psychiatry. 1997;42:976-981.

53. Denys D, Fluitman S, Kavelaars A, Heijn C, Westenberg H. Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. Psychoneuroendocrinology. 2004;29:945-952.

54. Monteleone P, Catapano F, Tortorella A, Maj M. Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder. Neuropsychobiology. 1998;37:182-185.

55. Rickards H, Durkan MJ, Farrar G, Betts T, Corbett JA, Handley SL. Increased plasma kynurenine and its relationship to neopterin and tryptophan in Tourette’s syndrome. Psychol Med. 1996;26:857-862.

56. Hoekstra R, Dekkers D, de van Wetering BJ, Peppinkhuizen L, Verhoeven WM. Effect of light therapy on biopterin, neopterin and tryptophan in patients with seasonal affective disorder. Psychiatry Res. 2003;120:37-42.
Tourette’s syndrome: clinical and therapeutic aspects - Müller

64. Martino D, Church AJ, Defazio G, et al. Soluble adhesion molecules in Gilles de la Tourette’s syndrome. J Neurol Sci. 2005;234:79-85.
65. Müller N. Anti-inflammatory therapy with a COX-2 inhibitor in Tourette’s syndrome. Inflammopharmacology. 2004;12:271-275.
66. Riedel M, Straube A, Schwarz MJ, Wiliske B, Müller N. Lyme disease presenting as Tourette’s syndrome. Lancet. 1998;351:418-419.
67. Müller N, Riedel M, Straube A, Wiliske B. Poststreptococcal autoimmune phenomena in patients with Tourette Syndrome. Psychi Res. 2000;94:43-49.

68. Müller N, Riedel M, Blendinger C, Oberle K, Jacobs E, Abele-Horn M. Mycoplasma pneumoniae infection and Tourette’s syndrome. Psychiatry Res. 2004;129:119-125.
69. Murphy ML, Pichichero ME. Prospective identification and treatment of children with pediatric autoimmune neuropsychiatric disorder associated with group A streptococcal infection (PANDAS). Arch Pediatr Adolesc Med. 2002;156:356-361.
70. Swedo SE, Leonard HL, Mittleman BB, et al. Identification of children with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections by a marker associated with rheumatic fever. Am J Psychiatry. 1997;154:110-112.
71. Kurlan R. Tourette’s syndrome and ‘PANDAS’: will the relation bear out? Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection [see comments]. Neurology. 1998;50:1530-1534.
72. Perlmutter SJ, Leitman SF, Garvey MA, et al. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet. 1999;354:1153-1158.
73. Singer HS, Giuliani JD, Hansen BH, et al. Antibodies against human putamen in children with Tourette Syndrome. Neurology. 1998;50:1618-1624.
74. Müller N, Riedel M, Forderreuther S, Blendinger C, Abele-Horn M. Tourette’s syndrome and mycoplasma pneumoniae infection. Am J Psychiatry. 2000;157:481-482.
75. Church AJ, Dale RC, Lees AJ, Giovannoni G, Robertson MM. Tourette’s syndrome: a cross sectional study to examine the PANDAS hypothesis. J Neurol Neurosurg Psychiatry. 2003;74:602-607.
76. Müller N, Krietsch B, Schwarz MJ, et al. Increased titers of antibodies against streptococcal M12 and M19 proteins in patients with Tourette’s syndrome. Psychiatry Res. 2001;101:187-193.
77. Greenberg BD, Murphy DL, Swedo SE. Symptom exacerbation of vocal tics and other symptoms associated with streptococcal pharyngitis in a patient with obsessive-compulsive disorder and tics. Am J Psychiatry. 1998;155:1459-1460.
78. Bodner SM, Morshed SA, Peterson BS. The question of PANDAS in adults. Biol Psychiatry. 2001;49:807-810.
79. Singer HS, Walkup JT. Tourette syndrome and other tic disorders. Diagnosis, pathophysiology, and treatment. Medicine (Baltimore). 1991;70:15-32.
80. Sandor P, Musisi S, Moldofsky H, Lang A. Tourette syndrome: a follow-up study. J Clin Psychopharmacol. 1990;10:197-199.
81. Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain. 2000;123 Pt 3:425-462.
82. Bruun RD, Budman CL. Risperidone as a treatment for Tourette’s syndrome. J Clin Psychiatry. 1996;57:29-31.
83. Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourette’s syndrome: clinical and therapeutic aspects - Müller Dialogues in Clinical Neuroscience - Vol 9. 2007:25:94-96.
84. Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol. 2005;8:489-490.
85. Dehning S, Riedel M, Müller N. Aripiprazole in a patient vulnerable to side effects. Am J Psychiatry. 2005;162:625.
86. Chouza C, Romero S, Lorenzo J, et al. [Clinical trial of tiapride in patients with dyskinesia (author’s transl)]. Sem Hop, 1982;58:725-733.
87. Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci. 1988;237:223-229.
88. Martino D, Church AJ, Defazio G, et al. Soluble adhesion molecules in Gilles de la Tourette’s syndrome. J Neurol Sci. 2005;234:79-85.
89. Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol. 2005;8:489-490.
90. Dehning S, Riedel M, Müller N. Aripiprazole in a patient vulnerable to side effects. Am J Psychiatry. 2005;162:625.
91. Chouza C, Romero S, Lorenzo J, et al. [Clinical trial of tiapride in patients with dyskinesia (author’s transl)]. Sem Hop, 1982;58:725-733.
92. Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci. 1988;237:223-229.
93. Leckman JF, Detlor J, Harcherik DF, Ort S, Shaywitz BA, Cohen D. Short- and long-term treatment of Tourette’s syndrome with clonidine: a clinical perspective. Neurology. 1985;35:343-351.
94. Goetz CG, Tanner CM, Wilson RS, Carroll VS, Como PG, Shannon KM. Clonidine and Gilles de la Tourette’s syndrome: double-blind study using objective rating methods. Ann Neurol. 1987;21:307-310.
95. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette’s syndrome with clonidine and neuroleptics. Arch Gen Psychiatry. 1983;40:1235-1240.
96. Müller-Vahl KR, Schneider U, Koblenz A, et al. Treatment of Tourette’s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002;35:57-61.
97. Wilhelm S, Deckerbach T, Coffey BJ, Bohne A, Peterson AL, Baer L. Habit reversal versus supportive psychotherapy for Tourette’s disorder: a randomized controlled trial. Am J Psychiatry. 2003;160:1175-1177.
98. Müller N, Riedel M, Erfurth A, Müller HJ. Immunoglobulin therapy in Gilles de la Tourette syndrome. Nervenarzt. 1997;68:914-916.
99. Müller N, Riedel M, Blendinger C, Forderreuther S, Abele-Horn M. Childhood Tourette syndrome: a comparison. Eur Arch Psychiatry Neurol Sci. 1998;248:1-12.
100. Cerveri, A, Michler A, Riedel M, Müller N. Immunomodulatory therapy in Tourette’s disorder - a comparison. Eur Arch Psychiatry Clin Neurosci. 2006;256:2. Abstract.
101. Mantovani A, Lisany SH, Pieraccini F, Ulivelli M, Castrogiovanni P, Rossi S. Repetitive transcranial magnetic stimulation (rTMS) in the treatment of obsessive-compulsive disorder (OCD) and Tourette’s syndrome (TS). Int J Neuropsychopharmacol. 2006;9:95-100.
102. Munchau A, Bloem BR, Thilo KV, Trimble MR, Rothwell JC, Robertson MM. Repetitive transcranial magnetic stimulation for Tourette syndrome. Neurology. 2002;59:1789-1791.
103. Chae JH, Nahas Z, Wassermann E, Li X, et al. A pilot safety study of repetitive transcranial magnetic stimulation (rTMS) in Tourette’s syndrome. Cogn Behav Neurol. 2004;17:109-117.
104. Rapoport M, Feder V, Sandor P. Response of major depression and Tourette’s syndrome to ECT: a case report. Psychosom Med. 1998;60:528-529.
105. Trivedi HK, Mendlewicz AJ, Fink M. Gilles de la Tourette’s syndrome of catatonia: response to ECT: J ECT. 2003;19:115-117.
106. Strassing M, Riedel M, Müller N. Electroconvulsive therapy in a patient with Tourette’s syndrome and co-morbid obsessive compulsive disorder. World J Biol Psychiatry. 2004;5:164-166.
107. Visser-VandeWalle V, Ackermans L, van der LC, et al. Deep brain stimulation in Gilles de la Tourette’s syndrome. Neurosurgery. 2006;58:E590.
108. Ackermans L, Temel Y, Cath D, et al. Deep brain stimulation in Tourette’s syndrome: two targets? Mov Disord. 2006;21:709-713.
109. Houeto JL, Karachi C, Mallet L, et al. Tourette’s syndrome and deep brain stimulation. J Neurol Neurosurg Psychiatry. 2005;76:992-995.
110. Diederich NJ, Kalteis K, Stamenkovic M, Pieri V, Alesch F. Efficient internal pallidal stimulation in Gilles de la Tourette syndrome: a case report. Mov Disord. 2005;20:1496-1499.
111. Sturm V, Lenartz D, Koulskais A, et al. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsive- and anxiety-disorders. J Chem Neuroanat. 2003;26:293-299.
112. Fathery AW, Williams ZM, Aminovin R, et al. Deep brain stimulation of the anterior internal capsule for the treatment of Tourette syndrome: technical case report. Neurosurgery. 2005;57:E403.